TIDMAGY

RNS Number : 5040L

Allergy Therapeutics PLC

03 October 2016

3 October 2016

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

Issue of equity in respect of the exercise of options

Allergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces the issue and allotment of 3,441,000 new ordinary shares of 0.1p each in the capital of the Company ("Ordinary Shares") pursuant to the exercise of 3,441,000 share options by certain employees. Of this number of share options, an amount of the share options have been exercised by persons discharging management responsibility ("PDMRs").

At the same time, the Company has received notice from certain PDMRs that they have immediately sold Ordinary Shares in respect of the share options exercised.

The exercise of share options and the sale of Ordinary Shares by the respective PDMRs are detailed below:

 
                                                                                   Resulting 
                          Ordinary                                                percentage 
                            Shares                                 Resulting       of voting 
                          received                      Price     beneficial          rights 
                     upon exercise   Ordinary    per Ordinary        holding          in the 
                          of share     Shares           share    of Ordinary         Company 
 PDMR                      options       sold            sold         Shares    at Admission 
-----------------  ---------------  ---------  --------------  -------------  -------------- 
 Sue Baker                 160,000    160,000           19.0p         27,900           0.01% 
-----------------  ---------------  ---------  --------------  -------------  -------------- 
 Alastair 
  Friend                    80,000     80,000           19.5p              -               - 
-----------------  ---------------  ---------  --------------  -------------  -------------- 
 Nunzio Di 
  Grazia                   452,500    452,500           19.5p              -               - 
-----------------  ---------------  ---------  --------------  -------------  -------------- 
 Bev Lees                  160,000    160,000           19.5p              -               - 
-----------------  ---------------  ---------  --------------  -------------  -------------- 
 Russell Pickett           160,000    160,000           19.5p              -               - 
-----------------  ---------------  ---------  --------------  -------------  -------------- 
 Santiago 
  Puig                     452,500    452,500           19.5p              -               - 
-----------------  ---------------  ---------  --------------  -------------  -------------- 
 Murray Skinner            160,000    160,000           19.5p              -               - 
-----------------  ---------------  ---------  --------------  -------------  -------------- 
 Bodo Steinert             452,500    226,250           19.5p        388,262           0.07% 
-----------------  ---------------  ---------  --------------  -------------  --------------

Application has been made to the London Stock Exchange for admission to trading of the 3,441,000 new Ordinary Shares on AIM ("Admission") in respect of the exercise of the share options. It is expected that Admission will take place and that dealings in the new Ordinary Shares on AIM will commence at 8:00 a.m. on 6 October 2016, at which time the sale of Ordinary Shares will occur. The new Ordinary Shares will, when issued, be credited as fully paid and will rank pari passu in all respects with the existing Ordinary Shares in the capital of the Company, including the right to receive all dividends or other distributions made, paid or declared in respect of such shares after the date of issue of the new Ordinary Shares.

Allergy Therapeutics' enlarged issued ordinary share capital immediately following Admission will be 593,364,020 Ordinary Shares with voting rights attached. The Company has no Ordinary Shares in Treasury; therefore, the total number of voting rights in Allergy Therapeutics is 593,364,020. This figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify an interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

- ENDS -

For further information, please contact:

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Finance Director

Panmure Gordon

+44 (0) 20 7886 2500

Freddy Crossley / Duncan Monteith, Corporate Finance

Tom Salvesen, Corporate Broking

Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott / Ivar Milligan / Matthew Neal / Laura Thornton

allergytherapeutics@consilium-comms.com

Note to editors:

About Allergy Therapeutics

Allergy Therapeutics is an international specialty pharmaceutical company focussed on the treatment and diagnosis of allergic disorders including immunotherapy vaccines that cure disease. The Company sells proprietary products and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with MHRA-approved manufacturing facilities. The Company employs c.420 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHEAEEDEAKKFFF

(END) Dow Jones Newswires

October 03, 2016 06:28 ET (10:28 GMT)

Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Allergy Therapeutics Charts.
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Allergy Therapeutics Charts.